Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 134

1.

Icatibant, a new bradykinin-receptor antagonist, in hereditary angioedema.

Cicardi M, Banerji A, Bracho F, Malbrán A, Rosenkranz B, Riedl M, Bork K, Lumry W, Aberer W, Bier H, Bas M, Greve J, Hoffmann TK, Farkas H, Reshef A, Ritchie B, Yang W, Grabbe J, Kivity S, Kreuz W, Levy RJ, Luger T, Obtulowicz K, Schmid-Grendelmeier P, Bull C, Sitkauskiene B, Smith WB, Toubi E, Werner S, Anné S, Björkander J, Bouillet L, Cillari E, Hurewitz D, Jacobson KW, Katelaris CH, Maurer M, Merk H, Bernstein JA, Feighery C, Floccard B, Gleich G, Hébert J, Kaatz M, Keith P, Kirkpatrick CH, Langton D, Martin L, Pichler C, Resnick D, Wombolt D, Fernández Romero DS, Zanichelli A, Arcoleo F, Knolle J, Kravec I, Dong L, Zimmermann J, Rosen K, Fan WT.

N Engl J Med. 2010 Aug 5;363(6):532-41. doi: 10.1056/NEJMoa0906393. Erratum in: N Engl J Med. 2010 Oct 7;363(15):1486.

2.

Repeat treatment with icatibant for multiple hereditary angioedema attacks: FAST-2 open-label study.

Baş M, Greve J, Hoffmann TK, Reshef A, Aberer W, Maurer M, Kivity S, Farkas H, Floccard B, Arcoleo F, Martin L, Sitkauskiene B, Bouillet L, Schmid-Grendelmeier P, Li H, Zanichelli A.

Allergy. 2013 Nov;68(11):1452-9. doi: 10.1111/all.12244. Epub 2013 Sep 21.

3.

Randomized placebo-controlled trial of the bradykinin B₂ receptor antagonist icatibant for the treatment of acute attacks of hereditary angioedema: the FAST-3 trial.

Lumry WR, Li HH, Levy RJ, Potter PC, Farkas H, Moldovan D, Riedl M, Li H, Craig T, Bloom BJ, Reshef A.

Ann Allergy Asthma Immunol. 2011 Dec;107(6):529-37. doi: 10.1016/j.anai.2011.08.015. Epub 2011 Oct 5.

PMID:
22123383
4.

Repeat treatment of acute hereditary angioedema attacks with open-label icatibant in the FAST-1 trial.

Malbrán A, Riedl M, Ritchie B, Smith WB, Yang W, Banerji A, Hébert J, Gleich GJ, Hurewitz D, Jacobson KW, Bernstein JA, Khan DA, Kirkpatrick CH, Resnick D, Li H, Fernández Romero DS, Lumry W.

Clin Exp Immunol. 2014 Aug;177(2):544-53. doi: 10.1111/cei.12358.

5.

Icatibant.

Deeks ED.

Drugs. 2010;70(1):73-81. doi: 10.2165/11204500-000000000-00000.

PMID:
20030426
6.

Management of acute attacks of hereditary angioedema: potential role of icatibant.

Longhurst HJ.

Vasc Health Risk Manag. 2010 Sep 7;6:795-802. Review.

7.

Icatibant for Multiple Hereditary Angioedema Attacks across the Controlled and Open-Label Extension Phases of FAST-3.

Lumry WR, Farkas H, Moldovan D, Toubi E, Baptista J, Craig T, Riedl M.

Int Arch Allergy Immunol. 2015;168(1):44-55. doi: 10.1159/000441060. Epub 2015 Nov 11.

8.

Icatibant for the treatment of hereditary angioedema.

Cole SW, Lundquist LM.

Ann Pharmacother. 2013 Jan;47(1):49-55. doi: 10.1345/aph.1R423. Epub 2012 Dec 18. Review.

PMID:
23249729
9.

Treatment of hereditary angioedema with icatibant: efficacy in clinical trials versus effectiveness in the real-world setting.

Maurer M, Longhurst HJ, Fabien V, Li HH, Lumry WR.

Allergy Asthma Proc. 2014 Sep-Oct;35(5):377-81. doi: 10.2500/aap.2014.35.3780. Epub 2014 Aug 6.

PMID:
25198193
10.

Icatibant. Attacks of hereditary angioedema: continue to use C1 esterase inhibitor.

[No authors listed]

Prescrire Int. 2010 Nov;19(110):245-7. Review.

PMID:
21284353
11.

Subcutaneous Icatibant for the Treatment of Hereditary Angioedema Attacks: Comparison of Home Self-Administration with Administration at a Medical Facility.

Otani IM, Lumry WR, Hurwitz S, Li HH, Craig TJ, Holtzman NS, Iandoli MI, Tucker J, Riedl MA, Zuraw BL, Banerji A.

J Allergy Clin Immunol Pract. 2017 Mar - Apr;5(2):442-447.e1. doi: 10.1016/j.jaip.2016.09.023. Epub 2016 Nov 3.

PMID:
27818136
12.

A randomized trial of icatibant in ACE-inhibitor-induced angioedema.

Baş M, Greve J, Stelter K, Havel M, Strassen U, Rotter N, Veit J, Schossow B, Hapfelmeier A, Kehl V, Kojda G, Hoffmann TK.

N Engl J Med. 2015 Jan 29;372(5):418-25. doi: 10.1056/NEJMoa1312524.

13.

Icatibant for hereditary angioedema.

Gras J.

Drugs Today (Barc). 2009 Dec;45(12):855-64. doi: 1396674/dot.2009.45.12.1424267. Review.

PMID:
20135020
14.

Treatment of acute edema attacks in hereditary angioedema with a bradykinin receptor-2 antagonist (Icatibant).

Bork K, Frank J, Grundt B, Schlattmann P, Nussberger J, Kreuz W.

J Allergy Clin Immunol. 2007 Jun;119(6):1497-503. Epub 2007 Apr 5.

PMID:
17418383
15.

Icatibant, an inhibitor of bradykinin receptor 2, for hereditary angioedema attacks: prospective experimental single-cohort study.

Campos RA, Valle SO, França AT, Cordeiro E, Serpa FS, Mello YF, Malheiros T, Toledo E, Mansour E, Fusaro G, Grumach AS.

Sao Paulo Med J. 2014;132(5):261-5. Epub 2014 Jul 22.

16.

Icatibant as acute treatment for hereditary angioedema in adults.

Farkas H.

Expert Rev Clin Pharmacol. 2016 Jun;9(6):779-88. doi: 10.1080/17512433.2016.1182425. Epub 2016 May 13. Review.

PMID:
27123689
17.
18.

Effect of bradykinin receptor antagonism on ACE inhibitor-associated angioedema.

Straka BT, Ramirez CE, Byrd JB, Stone E, Woodard-Grice A, Nian H, Yu C, Banerji A, Brown NJ.

J Allergy Clin Immunol. 2017 Jul;140(1):242-248.e2. doi: 10.1016/j.jaci.2016.09.051. Epub 2016 Nov 29.

PMID:
27913306
19.

Clinical efficacy of icatibant in the treatment of acute hereditary angioedema during the FAST-3 trial.

Baş M.

Expert Rev Clin Immunol. 2012 Nov;8(8):707-17. doi: 10.1586/eci.12.67.

PMID:
23167682
20.

Switch to icatibant in a patient affected by hereditary angioedema with high disease activity: a case report.

Firinu D, Barca MP, Serusi L, Lorrai MM, Peralta MM, Manconi PE, Del Giacco SR.

Int J Immunopathol Pharmacol. 2012 Jan-Mar;25(1):269-73.

PMID:
22507340

Supplemental Content

Support Center